Cohance Lifesciences passes all AGM resolutions including director reappointment
- Cohance Lifesciences passed all three ordinary resolutions at its 8th AGM held on September 17, 2026
- Shareholders approved the adoption of standalone and consolidated financial statements for FY26
- Ms. Shweta Jalan was reappointed as a director liable to retire by rotation
- Total votes polled stood at 317,125,944 shares, representing 82.89% participation
*this image is generated using AI for illustrative purposes only.
Cohance Lifesciences concluded its 8th Annual General Meeting on September 17, 2026, passing all three ordinary resolutions. The meeting, held via video conferencing, saw shareholders approve the standalone and consolidated financial statements for FY26 and the reappointment of Ms. Shweta Jalan as a director liable to retire by rotation.
The voting process, scrutinized by practicing company secretary D. Renuka, recorded high participation from institutional investors. Promoter and promoter group entities voted in favor of all resolutions, casting 100% of their eligible votes. Public institutions also showed strong support, particularly for the adoption of financial statements.
Voting Results Breakdown
The resolutions were passed with requisite majorities across all shareholder categories. The following table details the voting outcome for the reappointment of Ms. Shweta Jalan, which saw slightly higher dissent compared to the financial statement approvals.
| Resolution | Category | Votes In Favor | Votes Against | % In Favor |
|---|---|---|---|---|
| Adoption of Standalone Financials | Total | 317,123,341 | 2,603 | 99.9992% |
| Adoption of Consolidated Financials | Total | 317,123,341 | 2,603 | 99.9992% |
| Reappointment of Shweta Jalan | Total | 317,040,701 | 85,243 | 99.9731% |
Shareholder Participation
A total of 317,125,944 votes were polled out of 382,597,330 shares held as on the record date of September 10, 2026. This represents a polling percentage of approximately 82.89%. While promoter entities voted entirely through remote e-voting, public non-institutional shareholders utilized both remote e-voting and the insta-poll facility during the meeting.
Ms. Matangi Gowrishankar, independent director and chairperson of the Nomination and Remuneration Committee, and Mr. Vinod Rao, chairman of the Audit Committee, were among the directors present at the meeting. Executive Chairman and Group CEO Umang Vohra chaired the proceedings.
Historical Stock Returns for Cohance Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.62% | -0.77% | -0.16% | +49.92% | -55.59% | -18.23% |
How might the high institutional participation and near-unanimous approval signal future confidence in Cohance Lifesciences' strategic direction for FY27?
What specific operational or financial targets has management set to justify the reappointment of Ms. Shweta Jalan, given the slight increase in dissenting votes compared to financial approvals?
Could the 82.89% polling percentage indicate a broader trend of increased shareholder activism in mid-cap Indian pharmaceutical companies?
16
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
